Safety, tolerability and pharmacokinetic profile of Macozinone (PBTZ169) formulated as native crystal powder: multiple ascendingdoses, phase-Ib trial in healthy volunteers

Details

Request a copyRequest a copy
Serval ID
serval:BIB_F1F116FD908F
Type
Inproceedings: an article in a conference proceedings.
Collection
Publications
Institution
UNIL/CHUV
Title
Safety, tolerability and pharmacokinetic profile of Macozinone (PBTZ169) formulated as native crystal powder: multiple ascendingdoses, phase-Ib trial in healthy volunteers
Title of the conference
15th Congress of the European Association for Clinical Pharmacology and Therapeutics (EACPT) - June 2022 Athens. European Journal of Clinical Pharmacology, 2022, 78: 1-163
Author(s)
Chtioui H., Prod'Hom S., Desfontaine V., André P., Moulfi F., Bardinet C., Abo-Loha C., Tessieras J., Rothuizen L.E., Diezi L., Guidi M., Ivanyuk A., Decosterd L.A., Cole S., Buclin T.
Publication state
Published
Issued date
2022
Language
english
OAI-PMH
oai:serval.unil.ch:BIB_F1F116FD908F
Create date
13/01/2023 15:50
Last modification date
18/03/2023 6:45
Usage data